Enovis (ENOV) Stock Forecast, Price & News

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.

0 brokers have issued 1-year price targets for Enovis' shares. Their ENOV share price forecasts range from $10,000,000.00 to $0.00. On average, they predict the company's stock price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.

Enovis' stock was trading at $53.52 at the start of the year. Since then, ENOV stock has increased by 3.5% and is now trading at $55.38.
View the best growth stocks for 2023 here.

Enovis saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,810,000 shares, a decrease of 6.7% from the April 30th total of 1,940,000 shares. Based on an average daily volume of 481,900 shares, the short-interest ratio is currently 3.8 days. Approximately 3.7% of the shares of the company are short sold.
View Enovis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ENOV earnings forecast.

Enovis Co. (NYSE:ENOV) released its quarterly earnings results on Thursday, May, 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $406.20 million for the quarter, compared to analysts' expectations of $389.95 million. Enovis had a positive trailing twelve-month return on equity of 3.70% and a negative net margin of 3.24%. The company's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.37 earnings per share.

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap 400 Pure Value ETF (RFV), SPDR S&P Health Care Equipment ETF (XHE), Dimensional US Small Cap Value ETF (DFSV), First Trust Active Factor Small Cap ETF (AFSM), First Trust Horizon Managed Volatility Small/Mid ETF (HSMV), Hartford Schroders ESG US Equity ETF (HEET) and VictoryShares US Small Mid Cap Value Momentum ETF (USVM).

Enovis updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of $2.18-$2.32 for the period, compared to the consensus earnings per share estimate of $2.23. The company issued revenue guidance of -.

Enovis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENOV."

Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.49%), Dimensional Fund Advisors LP (5.32%), Diamond Hill Capital Management Inc. (3.97%), Thrivent Financial for Lutherans (2.86%), State Street Corp (2.70%) and Channing Capital Management LLC (2.54%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENOV stock can currently be purchased for approximately $55.38.

Enovis (NYSE:ENOV) has a market capitalization of $3.02 billion and generates $1.56 billion in revenue each year. The company earns $-13,290,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

The company employs 6,800 workers across the globe.

Enovis' mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The official website for the company is www.enovis.com. The company can be reached via phone at 302-252-9160, via email at investorrelations@colfaxcorp.com, or via fax at 301-323-9001.